^
Association details:
| Biomarker: | BRCA2 mutation |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | gemcitabine (DNA synthesis inhibitor) + Halaven (eribulin mesylate) (Microtubule inhibitor, CBP inhibitor, β-catenin inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)
Published date:
12/31/2020
Excerpt:
This is an open-label, multicenter phase II study evaluating the combination of eribulin (0.88 mg/m2) plus gemcitabine (1000 mg/m2) on days 1 and 8 of a 21-day cycle as either first- or second-line treatment of locally advanced or metastatic TNBC....the clinical benefit rate was 57.7% (90% CI 45.4-69.3) in wild-type patients and only 26.7% (90% CI 9.7-51.1) in BRCA-mutated ones (P = 0.043). Similarly, subjects with BRCA pathogenic variants were associated with significantly worse response duration, PFS, and OS than non-carriers...
DOI:
10.1016/j.esmoop.2020.100019
Trial ID:
